Riken Vitamin Co., Ltd.
Notice Regarding Revision of Earnings Guidance
Riken Vitamin Co., Ltd. announced a revision to its consolidated earnings guidance for the fiscal year ending March 2026, adjusting net sales to 96,000 million yen (down 4.0% from previous forecast), operating income to 6,200 million yen (down 27.1%), and net income attributable to owners of parent to 6,500 million yen (down 20.7%).
Key Figures
- Net Sales: 96,000 million yen (down 4,000 million yen, 4.0% from previous forecast)
- Operating Income: 6,200 million yen (down 2,300 million yen, 27.1% from previous forecast)
- Net Income Attributable to Owners of Parent: 6,500 million yen (down 1,700 million yen, 20.7% from previous forecast)
AI要約
Overview of Earnings Guidance Revision
Riken Vitamin Co., Ltd. has revised its consolidated earnings guidance for the fiscal year ending March 2026, lowering net sales to 96,000 million yen (down 4,000 million yen or 4.0% from the previous forecast), operating income to 6,200 million yen (down 2,300 million yen or 27.1%), ordinary income to 7,000 million yen (down 2,000 million yen or 22.2%), and net income attributable to owners of parent to 6,500 million yen (down 1,700 million yen or 20.7%). Net income per share is also expected to decrease to 219.84 yen.
Reasons for Revision and Future Outlook
The primary reasons for the revision are the significant underperformance expected in sales and operating income of overseas businesses due to sluggish consumption in China and intensified price competition in Europe and Southeast Asia. Additionally, a revision in the asset retirement obligation estimate related to asbestos removal costs in the third quarter is expected to substantially reduce operating income in the domestic food business. There is no change to the year-end dividend forecast for the fiscal year ending March 2026.
